Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer ...

Pfizer will publish full proposals of funded initiatives, in addition to any milestone updates, interim reports, final outcomes assessments and any other relevant, pertinent data and information that ...

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option NEW ...

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...

Pfizer Digital continuously seeks opportunities to bring fresh and innovative ideas to our business. The Digital Rotational Program is looking for recent college graduates to join our fast-paced ...

The Pfizer Futures assessment is designed to help us better understand your potential and identify candidates who may thrive within Pfizer's values-driven culture and future talent pipeline As part of ...

– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the ...

Cohort 3 analysis from the Phase 3 BREAKWATER study showed a 56% reduction in the risk of disease progression or death compared to traditional chemotherapy regimen Overall survival benefit was also ...

Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 ...

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...